Metabolic clearance and production rates of prolactin in man
- PMID: 583048
- PMCID: PMC371321
- DOI: 10.1172/JCI109629
Metabolic clearance and production rates of prolactin in man
Abstract
Metabolic clearance rates (MCR) and production rates (PR) of prolactin (PRL) have been determined by the constant infusion to equilibrium technique in 11 normal subjects, 6 patients with hyperthyroidism, 4 patients with hypothyroidism, and 9 patients with hyperprolactinemia. PRL MCR was also determined tin four patients during dopamine infusion. Mean PRL MCR was 46 +/- 1 ml/min per m2 in women and 44 +/- 3 ml/min per m2 in men, and was significantly correlated with body mass (r = 0.84, P less than 0.001). In contrast with controls, PRL MCR was higher in hyperthyroidism (MCR = 52 +/- 8 ml/min per m2, P less than 0.05), was slightly lower in hypothyroidism (MCR = 38 +/- 10 ml/min per m2, P = NS), and was significantly correlated with serum thyroxine (r = 0.46, P less than 0.02). PRL MCR was lower than controls in hyperprolactinemia (MCR = 40 +/- 5 ml/min per m2, P less than 0.01) and was inversely correlated with serum PRL (r = -0.72, P less than 0.001). PRL MCR was not significantly changed by dopamine infusion. Mean PRL PR for women and men was 211 +/- 74 and 187 +/- 44 micrograms/d per m2, respectively (P = NS). In hyperthyroidism the PRL PR was elevated (PR = 335 +/- 68 micrograms/d per m2, P less than 0.02), but in hypothyroidism the increase (PR = 233 +/- 159 micrograms/d per m2) was not significant. In hyperprolactinemia the PRL PR was extremely high (PR = 31,000 +/- 29,000 micrograms/d per m2). Dopamine infusion decreased RPL PR from 270 to 66 micrograms/d per m2 indicating that its effect was on pituitary PRL secretion and not PRL metabolism. To evaluate possible circulating PRL heterogeneity that might arise during infusion, gel filtration of infusate and serum obtained during the MCR procedure was performed. Labeled monomeric PRL (peak III, Kav (partition coefficient) = 0.4) was partially converted to two larger forms (peaks I and II) in vivo. Peak I (Kav = 0) was 30--40% immunoprecipitable, although peak II (Kav = 0.2) was not immunoprecipitable. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of peak I resulted in greater than or equal to 90% conversion to peak III and restoration of full immunoactivity. Thus, peak I is a noncovalently linked aggregate that is partially immunoactive, and therefore able to alter MCR determinations. These studies demonstrate the impact of hormone heterogeneity on MCR estimations and suggest that gel filtration of immunoprecipitable material be an integral part of future MCR measurements.
Similar articles
-
Metabolic clearance and secretion rates of subunits of human thyrotropin.J Clin Invest. 1977 Mar;59(3):508-16. doi: 10.1172/JCI108666. J Clin Invest. 1977. PMID: 838863 Free PMC article.
-
Pharmacokinetic studies of highly purified human prolactin in normal human subjects.J Clin Endocrinol Metab. 1987 Aug;65(2):299-304. doi: 10.1210/jcem-65-2-299. J Clin Endocrinol Metab. 1987. PMID: 3597709
-
The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects.J Clin Endocrinol Metab. 1986 Jan;62(1):202-9. doi: 10.1210/jcem-62-1-202. J Clin Endocrinol Metab. 1986. PMID: 2999177
-
Prolactin in men's health and disease.Curr Opin Urol. 2011 Nov;21(6):527-34. doi: 10.1097/MOU.0b013e32834bdf01. Curr Opin Urol. 2011. PMID: 21941183 Review.
-
Normal and abnormal prolactin metabolism.Clin Obstet Gynecol. 1978 Mar;21(1):125-37. doi: 10.1097/00003081-197803000-00010. Clin Obstet Gynecol. 1978. PMID: 24508 Review. No abstract available.
Cited by
-
Pituitary Hyperplasia Due to Longstanding Primary Hypothyroidism: A Case Report and Comprehensive Review of the Literature.Biomedicines. 2024 Jun 19;12(6):1368. doi: 10.3390/biomedicines12061368. Biomedicines. 2024. PMID: 38927575 Free PMC article.
-
Prolactin secretion in healthy adults is determined by gender, age and body mass index.PLoS One. 2012;7(2):e31305. doi: 10.1371/journal.pone.0031305. Epub 2012 Feb 17. PLoS One. 2012. PMID: 22363612 Free PMC article.
-
Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.J Endocrinol Invest. 1994 Jun;17(6):417-23. doi: 10.1007/BF03347728. J Endocrinol Invest. 1994. PMID: 7930386 Clinical Trial.
-
Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model.Br J Clin Pharmacol. 1986 Jul;22(1):1-13. doi: 10.1111/j.1365-2125.1986.tb02872.x. Br J Clin Pharmacol. 1986. PMID: 3755608 Free PMC article. Clinical Trial.
-
Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model.AAPS J. 2013 Apr;15(2):533-41. doi: 10.1208/s12248-012-9450-6. Epub 2013 Feb 8. AAPS J. 2013. PMID: 23392818 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous